Share on StockTwits

Investment Analysts’ ratings reiterations for Wednesday, July 16th:

Aegerion Pharmaceuticals (NASDAQ:AEGR) had its neutral rating reissued by analysts at Zacks. The firm currently has a $29.00 price target on the stock. Zacks’ analyst wrote, “Aegerion reported a loss of $0.54 per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of $0.35 but narrower than the year-ago loss of $0.64. Revenues of $26.9 million missed the Zacks Consensus Estimate of $34 million. Although the approval of Juxtapid is a major milestone for the company, sales are yet to pick up. Juxtapid’s first quarter sales were disappointing with the company cutting its 2014 guidance for the product. We remain concerned about the company’s dependence on Juxtapid for growth. While Aegerion is working on growing Juxtapid sales, we prefer remaining on the sidelines until we gain visibility on the impact of these efforts. We are initiating coverage on Aegerion with a Neutral recommendation.”

Aetna (NYSE:AET) had its buy rating reissued by analysts at Deutsche Bank. They currently have a $92.00 price target on the stock, up from their previous price target of $85.00.

Albemarle Corp. (NYSE:ALB) had its hold rating reiterated by analysts at Deutsche Bank. Deutsche Bank currently has a $75.00 target price on the stock, up from their previous target price of $72.00.

Albemarle Corp. (NYSE:ALB) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. They currently have a $70.00 target price on the stock, up from their previous target price of $65.00.

Ally Financial (NASDAQ:ALFI) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. They currently have a $32.00 price target on the stock, up from their previous price target of $30.00.

Applied Micro Circuits (NASDAQ:AMCC) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $11.00 target price on the stock. Zacks’ analyst wrote, “Applied Micro reported strong fourth quarter fiscal 2014 results with a healthy year-over-year increase in earnings. We believe that Applied Micro is well positioned to grow its market share based on its diversified product offerings, such as X-Gene and X-Weave products. In addition, the company’s strong associations with renowned server OEMs are expected to augment its business going forward. However, the competitive strides in the industry are likely to have a detrimental impact on its businesses. Management is also concerned about the continued macroeconomic challenges. Nevertheless, we maintain our long-term Neutral recommendation for the stock. “

Abercrombie & Fitch Co. (NYSE:ANF) had its neutral rating reissued by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $45.00 target price on the stock, up from their previous target price of $42.00.

Argonaut Gold (TSE:AR) had its buy rating reaffirmed by analysts at Desjardins. They currently have a C$5.00 target price on the stock, down from their previous target price of C$5.50.

American Express Company (NYSE:AXP) had its underweight rating reiterated by analysts at JPMorgan Chase & Co.. They currently have a $95.00 price target on the stock, up from their previous price target of $82.00.

C.R. Bard (NYSE:BCR) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $153.00 price target on the stock. Zacks’ analyst wrote, “CR Bard’s adjusted earnings rose 18.6% to $1.91 per share for the 2014-first quarter and beat the Zacks Consensus Estimate by $0.05 as well as its own guidance. Revenues grew 8.0% and comfortably outpaced the mark. On the back of better results, the company retained its bottom line guidance for 2014. It has also raised its dividend and expanded share repurchase program recently. Potential benefits from the Gore litigation are now expected in 2014. However, we remain concerned about the stringent sales environment in the U.S. Moreover, some of Bard’s businesses are experiencing significant pricing and competitive pressures and low-single digit growth in international markets. As a result, we reiterate our Neutral recommendation on CR Bard and set a target of $153.00.”

Coca-Cola Enterprises (NYSE:CCE) had its buy rating reaffirmed by analysts at Deutsche Bank. Deutsche Bank currently has a $52.00 price target on the stock, up from their previous price target of $50.00.

Celgene (NASDAQ:CELG) had its equal weight rating reiterated by analysts at Morgan Stanley. Morgan Stanley currently has a $75.00 price target on the stock. The analysts wrote, “Risks to EU patents may be underappreciated by consensus as Revlimid could go generic as early as 2022: There are three key groups of EU patents: (1) Composition (EP0925294) which expires 7/24/2017, but has supplementary protection (SPC) until 6/13/2022. The composition patents are not being challenged; (2) Methods for treating multiple myeloma (EP1505973) which expires 5/16/2023 and is being challenged by Synthon and an anonymous company; (3) Polymorph patent (EP1667682) which expires 9/3/2024 and is being challenged by Mylan and Teva. If generics succeed, Revlimid could go generic by June 2022.”

CIGNA (NYSE:CI) had its buy rating reissued by analysts at Deutsche Bank. The firm currently has a $105.00 target price on the stock, up from their previous target price of $95.00.

Comerica (NYSE:CMA) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $61.00 target price on the stock, up from their previous target price of $56.00.

Centene Corp (NYSE:CNC) had its hold rating reissued by analysts at Deutsche Bank. The firm currently has a $74.00 target price on the stock, up from their previous target price of $70.00.

Capital One Financial Corp. (NYSE:COF) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $95.00 target price on the stock, up from their previous target price of $85.00.

Coty (NYSE:COTY) had its buy rating reiterated by analysts at Deutsche Bank. The firm currently has a $20.00 price target on the stock, up from their previous price target of $18.00.

CSX (NYSE:CSX) had its neutral rating reissued by analysts at Citigroup Inc.. They currently have a $32.00 price target on the stock, up from their previous price target of $31.00.

Cousins Properties (NYSE:CUZ) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $13.00 target price on the stock. Zacks’ analyst wrote, “Cousins Properties is scheduled to release its second-quarter 2014 earnings results on Jul 30. The company again came up with an impressive performance in first-quarter 2014, with FFO per share exceeding both the Zacks Consensus Estimate and the prior-year quarter figure. A two-fold rise in quarterly revenues remained the driver. Notably, the company’s focus on simplifying its business by specifically targeting trophy assets and opportunistic investments is commendable. Moreover, the company has a strong balance sheet position. However, sluggish office space demand due to adequate space availability exerts pressure on rent and occupancies. Also, increasing Internet sales that adversely impact the demand for the company’s retail space could limit its growth prospects. Thus, our Neutral recommendation on the stock remains in place.”

Discover Financial Services (NYSE:DFS) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $65.00 target price on the stock, up from their previous target price of $59.00.

Eni SpA (NYSE:E) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $55.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on Eni SpA based on its recent international endeavors, partially offset by weak oil and gas fundamentals. In the first quarter, Eni’s earnings and revenues dropped year over year due to less production from mature fields and lower realized average prices. However, with the expected strengthening of the global economy, we believe that Eni can exploit opportunities to become profitable in the coming quarters. Furthermore, the significant discoveries in Mozambique, Cyprus, Congo, Ghana and Pakistan will continue to be accretive to earnings. However, the positives are partially mitigated by a weak economy in Europe, which is likely to impact its performances going forward. As such, we see limited upside potential for the stock and expect it to perform in line with the broader industry.”

Goldman Sachs (NYSE:GS) had its underweight rating reissued by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $150.00 target price on the stock, up from their previous target price of $148.00.

Goldman Sachs (NYSE:GS) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $178.00 target price on the stock. Zacks’ analyst wrote, “Driven by strong top-line performance, Goldman’s second-quarter 2014 earnings per share of $4.10 significantly surpassed the Zacks Consensus Estimate of $3.07. Moreover, results were above the year-ago figure of $3.70. Investment banking revenues were on an upswing. However, increase in expenses was experienced. We expect Goldman to benefit from its well-managed global franchise, strong capital base, and recent investments in the near future. After reviewing the results, we are maintaining our Neutral recommendation on the shares. “

Health Net (NYSE:HNT) had its hold rating reaffirmed by analysts at Deutsche Bank. The firm currently has a $41.00 target price on the stock, up from their previous target price of $37.00.

Hershey (NYSE:HSY) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. They currently have a $99.00 target price on the stock, down from their previous target price of $100.00.

Humana (NYSE:HUM) had its sell rating reaffirmed by analysts at Deutsche Bank. The firm currently has a $110.00 target price on the stock, up from their previous target price of $100.00.

IDEXX Laboratories (NASDAQ:IDXX) had its neutral rating reissued by analysts at Zacks. They currently have a $139.00 price target on the stock. Zacks’ analyst wrote, “IDEXX posted a mixed first quarter of 2014 with bottom line beat and revenue miss. EPS of $0.89 was up 8.5% year over year, also beating the Zacks Consensus Estimate by $0.01. Revenues of $360.2 billion increased 8% but missed the Zacks Consensus Estimate of $362 million. The year-over-year improvement was led by robust worldwide organic revenue growth of CAG. Backed by a strong and consistent CAG performance, the company also raised its fiscal 2014 revenue outlook. Strategic international expansion is another upside. Based on a strong cash position, the company also remains committed to delivering incremental returns to investors, thereby leveraging earnings power. However, dependence on third part distributors remains an overhang. Further, intense competition and currency fluctuations warrant caution. Thus, we Initiate IDEXX at Neutral. “

Intel (NASDAQ:INTC) had its equal weight rating reiterated by analysts at Barclays. Barclays currently has a $30.00 price target on the stock, up from their previous price target of $28.00.

Johnson & Johnson (NYSE:JNJ) had its buy rating reissued by analysts at Citigroup Inc.. The firm currently has a $122.00 price target on the stock, up from their previous price target of $117.00.

Johnson & Johnson (NYSE:JNJ) had its hold rating reiterated by analysts at Deutsche Bank. They currently have a $107.00 price target on the stock, up from their previous price target of $102.00.

Johnson & Johnson (NYSE:JNJ) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $108.00 price target on the stock. Zacks’ analyst wrote, “J&J beat expectations yet again with second-quarter earnings coming in at $1.66 per share, above the Zacks Consensus Estimate of $1.54 per share and 12.2% above the year-ago earnings. The company recorded growth on the back of strong pharma product sales with newly launched products like Olysio performing well. Sales jumped 9.1% year-over-year to $19.5 billion, beating the Zacks Consensus Estimate of $18.9 billion. With the company reporting strong results, earnings guidance was increased again. While we expect the company to continue facing headwinds in the form of pricing pressure, manufacturing issues, and U.S. healthcare reform, we believe the diversified business model, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We remain Neutral on the stock.”

JPMorgan Chase & Co. (NYSE:JPM) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $60.50 target price on the stock. Zacks’ analyst wrote, “JPMorgan braved the tough industry backdrop and seasonal softness with its underlying strength with earnings per share that beat the Zacks Consensus Estimate. In addition to seasonally soft trading volumes, there were legal costs and lower reserve release to drag the results, but top-line strength dominated. Also, its cost containment efforts were reflected in the non-interest expenses. Further, all business segments but for Consumer & Community Banking and Corporate and Investment Bank, witnessed year-over-year improvement in net income. After analyzing the company’s results, we maintain a Neutral recommendation on the stock.”

Kimberly Clark Corp (NYSE:KMB) had its hold rating reiterated by analysts at Deutsche Bank. Deutsche Bank currently has a $115.00 target price on the stock, up from their previous target price of $110.00.

Lightstream Resources (TSE:LTS) had its market perform rating reiterated by analysts at FirstEnergy Capital. FirstEnergy Capital currently has a C$7.50 price target on the stock, down from their previous price target of C$8.00.

Mercator Minerals (TSE:ML) had its hold rating reiterated by analysts at LB Securities. They currently have a C$0.05 target price on the stock, down from their previous target price of C$0.10.

Noble Co. New Common Stock – Switzerland (NYSE:NE) had its outperform rating reiterated by analysts at Credit Suisse. The firm currently has a $37.00 target price on the stock, up from their previous target price of $36.00.

National-Oilwell Varco (NYSE:NOV) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $88.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on National Oilwell Varco. We like its healthy backlog, solid balance sheet and strength in international operations, particularly in the Middle East and Brazil. The Robbins & Myers acquisition has further boosted NOV’s earnings visibility by expanding its blowout preventer product line a critical safety machine for a well. NOV’s proposal to split into two separate entities has added to the positive sentiment. However, we think the current valuation is fair and adequately reflects the company’s future growth prospects. Moreover, with markets remaining competitive and pricing likely to be weak, we see no obvious catalyst in NOV’s business to significantly push the stock price higher.”

Orexigen Therapeutics (NASDAQ:OREX) had its neutral rating reiterated by analysts at Zacks. They currently have a $5.50 target price on the stock. Zacks’ analyst wrote, “We are initiating coverage on Orexigen with a Neutral recommendation. Orexigen suffered a loss of $0.23 per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of $0.20 and the year-ago loss of $0.21. Revenues remained flat year over year at $0.9 million, in line with the Zacks Consensus Estimate. We are impressed by Orexigen’s efforts to bring its obesity candidate NB32 to market. Although we expect the drug to gain approval this time round, we prefer to remain on the sidelines until we gain visibility on the ramp up of NB32 once approved. Competition in the obesity market exists in the form of Belviq and Qsymia.”

PepsiCo (NYSE:PEP) had its buy rating reissued by analysts at Deutsche Bank. Deutsche Bank currently has a $96.00 target price on the stock, up from their previous target price of $94.00.

Spirit Airlines (NASDAQ:SAVE) had its buy rating reissued by analysts at Citigroup Inc.. The firm currently has a $76.00 price target on the stock, up from their previous price target of $67.00.

Sodastream International (NASDAQ:SODA) had its hold rating reissued by analysts at Deutsche Bank. Deutsche Bank currently has a $32.00 target price on the stock, down from their previous target price of $37.00.

Spectrum Brands Holdings (NYSE:SPB) had its buy rating reissued by analysts at Deutsche Bank. The firm currently has a $94.00 target price on the stock, up from their previous target price of $89.00.

Superior Energy Services (NYSE:SPN) had its buy rating reissued by analysts at Deutsche Bank. Deutsche Bank currently has a $43.00 price target on the stock, up from their previous price target of $39.00.

Universal American Corp. (NYSE:UAM) had its hold rating reiterated by analysts at Deutsche Bank. Deutsche Bank currently has a $8.00 target price on the stock, up from their previous target price of $7.50.

UnitedHealth Group (NYSE:UNH) had its buy rating reiterated by analysts at Deutsche Bank. Deutsche Bank currently has a $92.00 price target on the stock, up from their previous price target of $88.00.

Washington Federal (NASDAQ:WAFD) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $24.00 target price on the stock, up from their previous target price of $23.50.

WellPoint (NYSE:WLP) had its hold rating reissued by analysts at Deutsche Bank. The firm currently has a $110.00 price target on the stock, up from their previous price target of $105.00.

Wolverine World Wide (NYSE:WWW) had its sell rating reissued by analysts at Citigroup Inc.. They currently have a $24.00 target price on the stock, down from their previous target price of $26.00.

Yahoo! (NASDAQ:YHOO) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $37.00 price target on the stock. Zacks’ analyst wrote, “Yahoo! Inc. is one of the leading providers of web-based services and advertisements. Second-quarter earnings were in-line with the Zacks Consensus Estimate helped by a lower share count. Despite the uncertainty surrounding the search and the display business, we are encouraged by the company’s focus on product upgrades, acquisitions and growth initiatives that are improving engagement on Yahoo properties. Alibaba holdings will also generate cash that could keep the shares buoyant. However, the sluggish core business and the persistent pressure on prices continue to weigh on investor sentiments. We therefore have a Neutral rating on the shares.”

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.